| Lawrence Grill Mdpa | |
|
1166 River Ave Lakewood NJ 08701-5600 | |
| (732) 367-8272 | |
| Not Available |
| Full Name | Lawrence Grill Mdpa |
|---|---|
| Speciality | Internal Medicine |
| Location | 1166 River Ave, Lakewood, New Jersey |
| Authorized Official Name and Position | Kelly A Dennis (OFFICE MANAGER) |
| Authorized Official Contact | 7323678272 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lawrence Grill Mdpa 1166 River Ave Lakewood NJ 08701-5600 Ph: (732) 367-8272 | Lawrence Grill Mdpa 1166 River Ave Lakewood NJ 08701-5600 Ph: (732) 367-8272 |
| NPI Number | 1275561326 |
|---|---|
| Provider Enumeration Date | 06/29/2006 |
| Last Update Date | 06/12/2012 |
| Medicare PECOS PAC ID | 0749444966 |
|---|---|
| Medicare Enrollment ID | O20120619000313 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.
New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.
One puzzle in Alzheimer's disease (AD) research is why mice engineered to have the abnormal protein underlying the disease in humans show little pathology of the disease. Specifically, such mice are genetically altered to overproduce mutant human amyloid precursor protein (APP).
Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275561326 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Lawrence Grill |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1063443844 PECOS PAC ID: 8022041862 Enrollment ID: I20050913000840 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.
New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.
One puzzle in Alzheimer's disease (AD) research is why mice engineered to have the abnormal protein underlying the disease in humans show little pathology of the disease. Specifically, such mice are genetically altered to overproduce mutant human amyloid precursor protein (APP).
Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.
› Verified 6 days ago
News Archive
Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.
New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.
One puzzle in Alzheimer's disease (AD) research is why mice engineered to have the abnormal protein underlying the disease in humans show little pathology of the disease. Specifically, such mice are genetically altered to overproduce mutant human amyloid precursor protein (APP).
Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.
› Verified 6 days ago
Mini Mine Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 126 Melville Ave, Lakewood, NJ 08701 Phone: 732-886-8113 | |
Cassada Medical Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 475 Highway 70, Lakewood, NJ 08701 Phone: 732-886-6002 | |
First Aide Healthcare Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 109 E Harvard St, Lakewood, NJ 08701 Phone: 347-920-7834 | |
North Atlantic Medical Associates,pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 101 Prospect St, Suite 210, Lakewood, NJ 08701 Phone: 732-904-0077 | |
Ocean Health Initiatives Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 101 2nd St, Lakewood, NJ 08701 Phone: 732-363-6655 Fax: 732-363-6656 | |
Kimball Medical Center-physicians Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 600 River Ave, Lakewood, NJ 08701 Phone: 732-363-1900 Fax: 732-942-4422 | |
Jersey Shore Medical And Pediatrics Associates,llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1215 Highway 70, Suite 1005, Lakewood, NJ 08701 Phone: 732-942-0888 Fax: 732-942-1230 |